Physician profile
Khaled Janom
NPI 1528592128
$528.87
in general payments reported to CMS, 2019-2025
11 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $83.38 · 2024: $177 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.29 |
| Education | $118.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $134.56 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $82.12 | 2024-2025 | Krystexxa |
| Travere Therapeutics, INC. | $59.91 | 2024 | |
| Glaxosmithkline, LLC. | $57.77 | 2023-2025 | Benlysta, Nucala |
| Otsuka America Pharmaceutical, INC. | $41.79 | 2023 | Jynarque |
| Novartis Pharmaceuticals Corporation | $40.08 | 2025 | |
| Calliditas Therapeutics US INC. | $36.77 | 2025 | Tarpeyo |
| Ardelyx, INC. | $28.28 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $17.86 | 2025 | Velphoro |
| Nxstage Medical, INC. | $15.64 | 2025 | Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $14.09 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Janom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.